Relay Therapeutics, Inc.

RLAY Healthcare Biotechnology

Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.

Revenue
−95.4%
EPS
0.00%
Free cash flow
+2.13%

Quarter to June 2026, against a year earlier

18.44 1.44 +8.47%
Market cap
$3.7B
P/E
0.0×
Fwd P/E
−11.4×
Dividend yield
—
F-score
5/9
Altman Z
10.99
Beneish M
n/a
Dividend safety
n/a

Relay Therapeutics, Inc. (RLAY) Net margin

Alert me on Net margin

Relay Therapeutics, Inc.'s net margin over the twelve months to 30 June 2026 was −2,594.2%, down 793.6 percentage points from fiscal 2025 (−1,800.6%). Over the past ten years it has ranged from −21,036.1% (fiscal 2022) to 0.00% (fiscal 2019); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −1,800.6% 1,574.14
FY2024 −3,374.7% (2,036.06)
FY2023 −1,338.7% 19,697.47
FY2022 −21,036.1% (9,023.19)
FY2021 −12,012.9% (11,734.43)
FY2020 −278.5% (278.51)
FY2019 0.00% 0.00
FY2018 0.00% —

Quarterly newest first

Period Net margin Change (points)
Jun 2026 −23,916.3% (21,473.26)
Mar 2026 −2,443.0% (1,658.78)
Dec 2025 −784.3% (784.25)
Sep 2025 0.00% 10,395.13
24 more quarters

Against its own ten years

Low −21,036.1% High 0.00%
Ten-year median −1,569.6%
Current reading's percentile 50

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on RLAY